April 29, 2021: -Public preference for the AstraZeneca coronavirus vaccine has gone down since reports came, which should include some cases of unusual blood clotting events.
A study of nearly 5,000 adults in April in the U.K. has found that the public’s preference for the AstraZeneca Coronavirus vaccine has declined after March. The belief has increased that it causes blood clots.
The British academic study found 17% of the public now say they’d prefer AstraZeneca vaccine if they had a choice of any down from 24% by March-end.
And 23% of people now believe the AstraZeneca vaccine can cause blood clots, up from 13% in March.
The latest hurdles faced by the AstraZeneca vaccine were fewer reports of unusual blood clotting events, some of which were fatal, that emerged in post-vaccinated people in Europe in February, which led several countries to suspend the use of the vaccine.
The U.K. and EU drug regulators investigated the reports. They said while there was a possible link between the vaccine and a small number of blood clotting incidents, the vaccine’s benefits greatly outweighed the risks.
The British-Swedish vaccine maker, U.K. government, and experts largely defended the vaccine, saying that it had protected millions of people by reducing the number of Covid cases, hospitalizations, and deaths.
The U.K. is fortunate in that it has traditionally had a high level of public support for vaccinations. The survey on vaccine preference found that despite the growing belief that the AstraZeneca vaccine is linked to blood clots, it has not dented overall levels of confidence in vaccines in general, with 81% now saying vaccines are safe, compared with 73% who said the same toward the end of 2020.
We provide the insights on leaders who are responsible for taking their organization to new heights, all the while bringing together a group of talented individuals.
U.S. Steel has announced the indefinite idling of primary operations at its Granite City, Illinois, facility, which is expected to result in significant …
Sembcorp Industries Ltd., a Singapore-based energy company, has acquired more than 200 MW of operational wind power assets from Leap Green …
The Trusts, a community-owned liquor monopoly in West Auckland, is facing a strategic review of its $40 million expansion …
Paycor’s human capital management (HCM) platform modernizes every aspect of people management, from recruiting, onboarding, and payroll to career development and retention, but what really sets us apart is our focus on leaders.
In today’s day and age, there are numerous reports of increasing anxiety levels, low motivation, and exhaustion. But have we ever thought that the people struggling with those problems are the same people showing up to work at various organizations? This is not about a few employees just having a bad day.
HiBob is at the forefront of HR innovation, transforming the way organizations operate in the modern world of work with its award-winning HCM ‘Bob’. Its modular approach caters to the needs of multinational companies seeking agile technology and robust analytics to support operations across distributed workforces in the ever-evolving economic and workplace landscape.